Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2018

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Eluxadoline (Truberzi®) has been rejected for use in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D). The submitting company did not present a sufficiently robust economic analysis to gain acceptance

Metformin hydrochloride (Glucophage SR®) has been rejected for use to reduce the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose and/or increased HbA1C who are:

  • at high risk for developing overt type 2 diabetes mellitus and
  • still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months

The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2018' on Email Share 'SMC Update - January 2018' on Delicious Share 'SMC Update - January 2018' on Digg Share 'SMC Update - January 2018' on Facebook Share 'SMC Update - January 2018' on Google+ Share 'SMC Update - January 2018' on reddit Share 'SMC Update - January 2018' on StumbleUpon Share 'SMC Update - January 2018' on Twitter

atomic-wealth

No Comments to “SMC Update - January 2018”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer